
Opinion|Videos|May 1, 2026
Managing Fatigue with ARPIs in Metastatic Castration-Sensitive Prostate Cancer in the Clinic
This series explores how fatigue and other treatment-related adverse events influence quality of life and treatment persistence in metastatic castration-sensitive prostate cancer, with a focus on practical strategies for assessment, management, and supportive care in patients receiving ADT and ARPI-based therapy.
Episodes in this series

This series explores how fatigue and other treatment-related adverse events influence quality of life and treatment persistence in metastatic castration-sensitive prostate cancer, with a focus on practical strategies for assessment, management, and supportive care in patients receiving ADT and ARPI-based therapy.
Latest CME
Trending on Urology Times
1
Matthew Galsky, MD, on how EV/pembrolizumab is redefining the MIBC treatment paradigm
2
Cretostimogene Grenadenorepvec: Mechanism and Rationale
3
Published BOND-003 data show durable responses with cretostimogene in NMIBC
4
Pearls & Perspectives: From Prostate Cancer Diagnosis to Patient Advocacy, with Gabe Canales
5















